Todd Johanna E, Nguyen Sandra M
Medical Oncology, Small Animal Specialist Hospital, North Ryde, NSW, Australia.
JFMS Open Rep. 2020 Jun 12;6(1):2055116920924911. doi: 10.1177/2055116920924911. eCollection 2020 Jan-Jun.
Primary pancreatic adenocarcinoma is an uncommon neoplasm seen in cats and often has a poor prognosis. We report a case of an 8-year-old male neutered domestic shorthair cat weighing 5.8 kg diagnosed with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate, which had a progression-free interval of 1148 days and survived for more than 1436 days. The treatment was well tolerated; however, the cat developed generalised coat hypopigmentation.
To our knowledge, the cat in our report has the longest progression-free interval and survival time post-surgical resection of pancreatic carcinoma treated with toceranib. Hypopigmentation as a side effect of toceranib has been reported in dogs, but this is the first case reported in cats.
原发性胰腺腺癌是猫中少见的肿瘤，预后通常较差。我们报告一例8岁、体重5.8千克的已绝育家养短毛雄性猫，诊断为胰腺腺癌，接受了手术切除和磷酸托西拉尼治疗，无进展生存期为1148天，存活超过1436天。该治疗耐受性良好；然而，这只猫出现了全身被毛色素减退。
据我们所知，我们报告中的这只猫在接受磷酸托西拉尼治疗的胰腺癌手术切除后，具有最长的无进展生存期和生存时间。托西拉尼的副作用色素减退在犬中已有报道，但这是猫中首次报道的病例。
